Anti-leukotriene drugs in the therapy of inflammatory diseases

Bartłomiej Pyrak; Karolina Rogacka; Dariusz Maciej Pisklak

doi:10.56782/pps.38

Published : 2022-08-17

Vol. 20 No. 2 (2022)

Anti-leukotriene drugs in the therapy of inflammatory diseases

Bartłomiej Pyrak

Karolina Rogacka

Dariusz Maciej Pisklak

DOI: https://doi.org/10.56782/pps.38

Abstract

A key part of many chronic diseases is inflammation controlled by inflammatory mediators. Regulation of their function allows to mute the inflammatory response, which is a desired effect in the treatment of inflammatory diseases. The source of mediators is arachidonic acid, converted to pro-inflammatory mediators by cyclooxygenases (COX) or lipooxygenases (LOX). The 5-LOX pathway is full of target points for regulation of biosynthesis of cysteinyl leukotrienes (CysLT) – one of the major classes of inflammatory mediators. These compounds exert their activity through specific leukotriene receptors – first (CysLT₁R) and second (CysLT₂R). Drugs that inhibit CysLT synthesis as well as leukotriene receptors antagonists (LTRA) form group of drugs known as anti-leukotriene drugs. Currently, only a few representatives of this group are available in the pharmacies around the world: the 5-LOX inhibitor – zileuton – and three CysLT₁R antagonists – montelukast, pranlukast, zafirlukast. LTRAs due to their wide range of anti-inflammatory effects, are a group of drugs with a high potential in the treatment of inflammatory diseases. The study of new applications of known LTRAs and the search for new members of the LTRA group are the main directions of development in this field of pharmacy. This work summarizes the benefits of using anti-leukotriene drugs in the treatment od chronic diseases and presents new directions of using LTRAs.

Keywords:

cysteinyl leukotrienes, antagonism, anti-leukotriene drugs, COVID-19, mutations

Similar Articles

Paulina Oleksa, Daria Żuraw, Kacper Jasiński, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Karolina Haczkur-Pawłowska, Drugs and other chemical substances inducing diabetes – review of the literature , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula, The glucagon-like peptide-1 analogues therapy in the non-diabetic patients , Prospects in Pharmaceutical Sciences: Vol. 21 No. 1 (2023)
Paulina Brewczyńska, Justyna Makowska, Dorota Skrajnowska, Marta Teryks, Andrzej Tokarz, ADDICTION TO CONVENTIONAL AND ELECTRONIC CIGARETTES AND THE RISKS OF PHARMACOTHERAPY IN SMOKERS. , Prospects in Pharmaceutical Sciences: Vol. 13 No. 3 (2015)
Piotr Bojanowski, Piotr F. J. Lipiński, Paweł Czekała, Dariusz Plewczyński, MULTITARGET DRUGS – A NEW PARADIGM IN DRUG DESIGN , Prospects in Pharmaceutical Sciences: Vol. 11 No. 1 (2013)
Angelika Lis, Katarzyna Wyszomierska, Katarzyna Znajdek, Łukasz Szeleszczuk, Monika Zielińska-Pisklak, PHOTOSENSITIVITY PHENOMENON – A SIGNIFICANT ADVERSE EFFECT OF COMMONLY USED DRUGS , Prospects in Pharmaceutical Sciences: Vol. 19 No. 3 (2021)
Joanna Warguła, Outline of the history of drug synthesis with particular emphasis on anticancer and antibacterial drugs , Prospects in Pharmaceutical Sciences: Vol. 20 No. 3 (2022)
Anna Dominiczak, Agata Janczak, Martyna Wołek, Katarzyna Mazurek, Maciej Bara, Proton pump inhibitors: prolonged intake and adverse effects , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Aneta Emilia Jabłońska, Krzysztof Adam Stępień, COUNTERFEITING OF MEDICINAL PRODUCTS AND THREATS ASSOCIATED WITH THEIR TAKING , Prospects in Pharmaceutical Sciences: Vol. 17 No. 11 (2019)
Ewa Napiórkowska, Overview of cyclodextrins and medicinal products containing cyclodextrins currently registered in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Kinga Grużewska-Piotrowska, Agnieszka Grużewska, Medication overuse headache as a consequence of taking painkillers – a review of current literature , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)

1 2 3 4 5 6 7 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Pyrak, B., Rogacka, K., & Pisklak, D. M. (2022). Anti-leukotriene drugs in the therapy of inflammatory diseases. Prospects in Pharmaceutical Sciences, 20(2), 1–23. https://doi.org/10.56782/pps.38

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Kumar V.; Abbas A.K.; Aster J.C. Zapalenie i Naprawa Tkanek. W Robbins Patologia, 10th ed. Edra Urban & Partner, Polska, 2020; 65-110.

Abdulkhaleq L.A.; Assi M.A.; Abdullah R.; Zamri-Saad M.; Taufiq-Yap Y.H.; Hezmee M.N.M. The crucial roles of inflammatory mediators in inflammation: A review. Vet World 2018, 11(5):627-635, doi:10.14202/vetworld.2018.627-635 DOI: https://doi.org/10.14202/vetworld.2018.627-635

WHO. Non communicable Diseases. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (na dzień: 19 czerwca 2022).

Hallstrand T.S.; Henderson W.R. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010, 10(1):60-66, doi:10.1097/ACI.0b013e32833489c3 DOI: https://doi.org/10.1097/ACI.0b013e32833489c3

Hanna V.S.; Hafez E.A.A. Synopsis of arachidonic acid metabolism: A review. J. Adv. Res, 2018, 11:23-32, doi:10.1016/j.jare.2018.03.005 DOI: https://doi.org/10.1016/j.jare.2018.03.005

Samuelsson B. An Elucidation of the Arachidonic Acid Cascade. Drugs, 1987, 33(1):2-9, doi:10.2165/00003495-198700331-00003 DOI: https://doi.org/10.2165/00003495-198700331-00003

Calder P.C. Eicosanoids. Essays Biochem. 2020, 64(3):423-441, doi:10.1042/EBC20190083 DOI: https://doi.org/10.1042/EBC20190083

Evans J.F.; Ferguson A.D.; Mosley R.T.; Hutchinson J.H. What’s all the FLAP about?: 5-lipoxygenase-activating protein inhibi-tors for inflammatory diseases. Trends Pharmacol Sci. 2008, 29(2):72-78, doi:10.1016/j.tips.2007.11.006 DOI: https://doi.org/10.1016/j.tips.2007.11.006

Savari S.; Vinnakota K.; Zhang Y.; Sjölander A. Cysteinyl leukotrienes and their receptors: Bridging inflammation and colorectal cancer. World J Gastroenterol. 2014, 20(4):968-977, doi:10.3748/wjg.v20.i4.968 DOI: https://doi.org/10.3748/wjg.v20.i4.968

Bäck M.; Dahlén S.E.; Drazen J.M.; Evans J.F.; Serhan C.N.; Shimizu T.; Yokomizo T.; Rovati G.E. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Phar-macol Rev. 2011, 63(3):539-584, doi:10.1124/pr.110.004184 DOI: https://doi.org/10.1124/pr.110.004184

Araújo A.C.; Tang X.; Haeggström J.Z. Targeting cysteinyl-leukotrienes in abdominal aortic aneurysm. Prostaglandins Other Lipid Mediat. 2018, 139:24-28, doi:10.1016/j.prostaglandins.2018.09.007 DOI: https://doi.org/10.1016/j.prostaglandins.2018.09.007

Haeggström J.Z.; Funk C.D. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev. 2011, 111(10):5866-5898, doi:10.1021/cr200246d DOI: https://doi.org/10.1021/cr200246d

Kanaoka Y.; Austen K.F. Roles of cysteinyl leukotrienes and their receptors in immune cell-related functions. Adv Immunol. 2019, 142:65-84, doi:10.1016/bs.ai.2019.04.002 DOI: https://doi.org/10.1016/bs.ai.2019.04.002

Kanaoka Y.; Boyce J.A. Cysteinyl Leukotrienes and Their Receptors; Emerging Concepts. Allergy Asthma Immunol Res. 2014, 6(4):288-295, doi:10.4168/aair.2014.6.4.288 DOI: https://doi.org/10.4168/aair.2014.6.4.288

Singh R.K.; Gupta S.; Dastidar S.; Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology. 2010, 85(6):336-349, doi:10.1159/000312669 DOI: https://doi.org/10.1159/000312669

Jo-Watanabe A.; Okuno T.; Yokomizo T. The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders. Int J Mol Sci. 2019, 20(14):E3580, doi:10.3390/ijms20143580 DOI: https://doi.org/10.3390/ijms20143580

Reddanna P.; Prabhu K.S.; Whelan J.; Reddy C.C. Carboxypeptidase A-catalyzed direct conversion of leukotriene C4 to leukotriene F4. Arch Biochem Biophys. 2003, 413(2):158-163, doi:10.1016/s0003-9861(03)00080-8 DOI: https://doi.org/10.1016/S0003-9861(03)00080-8

Choi J.H.; Kim M.A.; Park H.S. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2014, 14(1):1-6, doi:10.1097/ACI.0000000000000021 DOI: https://doi.org/10.1097/ACI.0000000000000021

Capra V.; Carnini C.; Accomazzo M.R;, Di Gennaro A.; Fiumicelli M.;,Borroni E.; Brivio I.; Buccellati C.; Mangano P;, Carnevali S.; Rovati G.; Sala A. Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling througthe CysLT₂ receptor. Prostaglandins Other Lipid Mediat. 2015, 120:115-125, doi:10.1016/j.prostaglandins.2015.03.007 DOI: https://doi.org/10.1016/j.prostaglandins.2015.03.007

Colazzo F.; Gelosa P.; Tremoli E.; Sironi L.; Castiglioni L. Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases. Mediators Inflamm, 2017, 2017:2432958. doi:10.1155/2017/2432958 DOI: https://doi.org/10.1155/2017/2432958

Capra V.; Rovati G;, Mangano P.; Buccellati C,; Murphy R.C.; Sala A. Transcellular biosynthesis of eicosanoid lipid mediators. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2. 2015,1851(4):377-38,. doi:10.1016/j.bbalip.2014.09.002 DOI: https://doi.org/10.1016/j.bbalip.2014.09.002

Samuelsson B. The leukotrienes: a new group of biologically active compounds. Pure and Applied Chemistry, 1981, 53(6):1203-1213, doi:10.1351/pac198153061203 DOI: https://doi.org/10.1351/pac198153061203

Lynch K.R.; O’Neill G.P.; Liu Q. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999, 399(6738):789-793, doi:10.1038/21658 DOI: https://doi.org/10.1038/21658

Takasaki J.; Kamohara M.; Matsumoto.; Saito T.; Sugimoto T.; Ohishi T.; Ishii H.; Ota T.; Nishikawa T.; Kawai Y.; Masuho Y.; Isogai T.; Suzuki Y.; Sugano S.; Furuichi K. The molecular characterization and tissue distribution of the human cysteinyl leuko-triene CysLT(2) receptor. Biochem Biophys Res Commun. 2000, 274(2):316-322, doi:10.1006/bbrc.2000.3140 DOI: https://doi.org/10.1006/bbrc.2000.3140

Capra V.; Nicosia S.; Ragnini D.; Mezzetti M.; Keppler D.; Rovati G.E. Identification and characterization of two cyste-inyl-leukotriene high affinity binding sites with receptor characteristics in human lung parenchyma. Mol Pharmacol. 1998, 53(4):750-758, doi:10.1124/mol.53.4.750 DOI: https://doi.org/10.1124/mol.53.4.750

Heise C.E.; O’Dowd B.F.; Figueroa D.J.; Sawyer N.; Nguyen T.; Im D.S.; Stocco R.; Bellefeuille J.N.; Abramowitz M.; Cheng R.; Williams D.L.; Zeng Z.; Liu Q.; Ma L.; Clements M.K.; Coulombe N.; Liu Y.; Austin C.P.; George S.R.; O’Neill G.P.; Metters K.M.; Lynch K.R.; Evans J.F. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000, 275(39):30531-30536, doi:10.1074/jbc.M003490200 DOI: https://doi.org/10.1074/jbc.M003490200

Bankova L.G.; Lai J.; Yoshimoto E.; Austen K.F.; Kanaoka Y.; Barrett N.A. The Leukotriene E4 Receptor, GPR99 Mediates Mast Cell-Dependent Mucosal Responses to the Mold Allergen, Alternaria alternata. J. Allergy Clin. Immunol. 2016, 137(2):AB409, doi:10.1016/j.jaci.2015.12.1268 DOI: https://doi.org/10.1016/j.jaci.2015.12.1268

Kanaoka Y.; Maekawa A,.; Austen K.F. Identification of GPR99 Protein as a Potential Third Cysteinyl Leukotriene Receptor with a Preference for Leukotriene E4 Ligand. J Biol Chem. 2013, 288(16):10967-10972, doi:10.1074/jbc.C113.453704 DOI: https://doi.org/10.1074/jbc.C113.453704

Maekawa A.; Kanaoka Y.; Xing W.; Austen K.F. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 2008, 105(43):16695-16700, doi:10.1073/pnas.0808993105 DOI: https://doi.org/10.1073/pnas.0808993105

Rovati G.E.; Capra V. Cysteinyl-Leukotriene Receptors and Cellular Signals. Sci World J. 2007, 7:1375-1392. doi:10.1100/tsw.2007.185 DOI: https://doi.org/10.1100/tsw.2007.185

Chen K.; Yu Z.; Yang J.; Li H. Expression of cysteinyl leukotriene receptor GPR17 in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps. Asian Pac J Allergy Immunol. 2018, 36(2):93-100, doi:10.12932/AP-030417-0063 DOI: https://doi.org/10.12932/AP-030417-0063

Wu X.; Hong H.; Zuo K.; Han M.; Li J.; Wen W.; Xu G.; Miao B.; Li H. Expression of leukotriene and its receptors in eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2016, 6(1):75-81. doi:10.1002/alr.21625 DOI: https://doi.org/10.1002/alr.21625

Bäck M.; Powell W.S.; Dahlén S.E.; Drazen J.M.; Evans J.F.; Serhan C.N.; Shimizu T.; Yokomizo T.; Rovati G.E. Update on leuko-triene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol. 2014, 171(15):3551-3574, doi:10.1111/bph.12665 DOI: https://doi.org/10.1111/bph.12665

Hamanaka N. 1.07 - Eicosanoids in Mammals. W Comprehensive Natural Products Chemistry, 1st ed.; Barton S.D.; Nakanishi K.; Meth-Cohn O. eds.; Pergamon, United Kingdom, 1999, 159-206, doi:10.1016/B978-0-08-091283-7.00153-3 DOI: https://doi.org/10.1016/B978-0-08-091283-7.00153-3

Peters-Golden M.; Henderson W.R.; Leukotrienes. N Engl J Med. 2007, 357(18):1841-1854, doi:10.1056/NEJMra071371 DOI: https://doi.org/10.1056/NEJMra071371

Baptista-dos-Reis R.; Muniz V.S.; Neves J.S.; Multifaceted roles of cysteinyl leukotrienes in eliciting eosinophil granule protein secretion. Biomed Res Int. 2015, 2015:848762, doi:10.1155/2015/848762 DOI: https://doi.org/10.1155/2015/848762

Cobanoğlu B.; Toskala E.; Ural A.; Cingi C. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2013, 13(2):203-208, doi:10.1007/s11882-013-0341-4 DOI: https://doi.org/10.1007/s11882-013-0341-4

Du J.; Ba L.; Zhou J.; Yu L.; Liu R.; Zhang J.; Liu F.; Xian J.; Liu S.; Liu Y. The role of cysteinyl leukotrienes and their receptors in refractory nasal polyps. Prostaglandins Leukot Essent Fatty Acids. 2017, 126:39-48, doi:10.1016/j.plefa.2017.09.009 DOI: https://doi.org/10.1016/j.plefa.2017.09.009

Neves J.S.; Radke A.L.; Weller P.F.; Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. J Allergy Clin Immunol. 2010, 125(2):477-482, doi:10.1016/j.jaci.2009.11.029 DOI: https://doi.org/10.1016/j.jaci.2009.11.029

Ichiyama T.; Kajimoto M.; Hasegawa M.; Hashimoto K.; Matsubara T.; Furukawa S. Cysteinyl leukotrienes enhance tumour necro-sis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clin Exp Allergy. 2007, 37(4):608-614, doi:10.1111/j.1365-2222.2007.02692.x DOI: https://doi.org/10.1111/j.1365-2222.2007.02692.x

Lagente V.; Boichot E. Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J Mol Cell Cardiol. 2010, 48(3):440-444, doi:10.1016/j.yjmcc.2009.09.017 DOI: https://doi.org/10.1016/j.yjmcc.2009.09.017

Cingi C.; Muluk N.B.; Ipci K.; Şahin E. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015, 15(11):64, doi:10.1007/s11882-015-0564-7 DOI: https://doi.org/10.1007/s11882-015-0564-7

Theron A.J.; Steel H.C.; Tintinger G.R.; Gravett C.M.; Anderson R.; Feldman C. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res. 2014, 2014:608930. doi:10.1155/2014/608930 DOI: https://doi.org/10.1155/2014/608930

Sokolowska M.; Rovati G.E.; Diamant Z.; Untersmayr E.; Schwarze J.; Lukasik Z.; Sava F.; Angelina A.; Palomares O.; Akdis C.A..; O’Mahony L.; Sanak M.; Dahlen S.E.; Woszczek G. Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. Allergy. 2021, 76(1):114-130, doi:10.1111/all.14295 DOI: https://doi.org/10.1111/all.14295

Hon K.L.E.; Leung T.F.; Leung A.K.C. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des Devel Ther, 2014, 8:839-850, doi:10.2147/DDDT.S39100 DOI: https://doi.org/10.2147/DDDT.S39100

Ducharme F.M.; Lasserson T.J.; Cates C.J. Addition to inhaled corticosteroids of long-acting beta2-agonists versus an-ti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2011, (5):CD003137, doi:10.1002/14651858.CD003137.pub4 DOI: https://doi.org/10.1002/14651858.CD003137.pub4

Choi G.S.; Kim J.H.; Shin Y.S.; Ye Y.M.; Kim S.H.; Park H.S.; Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. Clin Exp Allergy. 2013, 43(7):730-740, doi:10.1111/cea.12096 DOI: https://doi.org/10.1111/cea.12096

Choby G.W.; Lee S. Pharmacotherapy for the treatment of asthma: current treatment options and future directions. Int Forum Al-lergy Rhinol. 2015, 5 Suppl 1:S35-40, doi:10.1002/alr.21592 DOI: https://doi.org/10.1002/alr.21592

Pyasi K.; Tufvesson E.; Moitra S. Evaluating the role of leukotriene-modifying drugs in asthma management: Are their benefits “losing in translation”? Pulm Pharmacol Ther. 2016, 41:52-59, doi:10.1016/j.pupt.2016.09.006 DOI: https://doi.org/10.1016/j.pupt.2016.09.006

Dahlén B.; Nizankowska E.; Szczeklik A.; Zetterström O.; Bochenek G.; Kumlin M.; Mastalerz L.; Pinis G.; Swanson L.J.; Bood-hoo T.I.; Wright S.; Dube L.M.; Dahlen S.E. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998, 157(4 Pt 1):1187-1194, doi:10.1164/ajrccm.157.4.9707089 DOI: https://doi.org/10.1164/ajrccm.157.4.9707089

Hallstrand T.S.; Henderson W.R.; Role of leukotrienes in exercise-induced bronchoconstriction. Curr Allergy Asthma Rep. 2009, 9(1):18-25, doi:10.1007/s11882-009-0003-8 DOI: https://doi.org/10.1007/s11882-009-0003-8

Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention NIH Pub. No 02–3659, January 1995 (2018 Update). https://ginasthma.org/wp-content/uploads/2019/01/2018-GINA.pdf (na dzień: 19 czerwca 2022)

Peters-Golden M.; Swern A.; Bird S.S.; Hustad C.M.; Grant E.; Edelman J.M.; Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006, 27(3):495-503, doi:10.1183/09031936.06.00077205 DOI: https://doi.org/10.1183/09031936.06.00077205

Diamant Z.; Aalders W.; Parulekar A.; Bjermer L.; Hanania N.A. Targeting lipid mediators in asthma: time for reappraisal. Curr Opin Pulm Med. 2019, 25(1):121-127. doi:10.1097/MCP.0000000000000544 DOI: https://doi.org/10.1097/MCP.0000000000000544

Shirasaki H.; Himi T. Role of Cysteinyl Leukotrienes in Allergic Rhinitis. Adv Otorhinolaryngol. 2016, 77:40-45, doi:10.1159/000441871 DOI: https://doi.org/10.1159/000441871

Roquet A.; Dahlén B.; Kumlin M.; Ihre E.; Anstren G.; Binks S.; Dahlen S.E. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med. 1997, 155(6):1856-1863, doi:10.1164/ajrccm.155.6.9196086 DOI: https://doi.org/10.1164/ajrccm.155.6.9196086

Kim M.K.; Lee S.Y.; Park H.S.; Yoon H.J.; Kim S.H.; Cho Y.J.; Yoo K.H.; Lee S.K.; Kim H.K.; Park J.W.; Chung J.G.; Choi B.W.; Lee B.J.; Chang Y.S.; Jo E.J.; Lee S.Y.; Cho Y.S.; Jee J.M.; Jung J.; Park C.S. A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Pa-tients With Asthma and Allergic Rhinitis. Clin Ther. 2018, 40(7):1096-1107.e1, doi:10.1016/j.clinthera.2018.04.021 DOI: https://doi.org/10.1016/j.clinthera.2018.04.021

Noonan M.J.; Chervinsky P.; Brandon M.; Zhang J.; Kundu S.; McBurney J.; Reiss T.F. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J. 1998, 11(6):1232-1239, doi:10.1183/09031936.98.11061232 DOI: https://doi.org/10.1183/09031936.98.11061232

Miligkos M.; Bannuru R.R.; Alkofide H.; Kher S.R.; Schmid C.H.; Balk E.M. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med. 2015, 163(10):756-767, doi:10.7326/M15-1059 DOI: https://doi.org/10.7326/M15-1059

Pasaoglu G.; Mungan D.; Abadoglu O.; Misirligil Z. Leukotriene receptor antagonists: a good choice in the treatment of premen-strual asthma? J Asthma. 2008, 45(2):95-99, doi:10.1080/02770900701751799 DOI: https://doi.org/10.1080/02770900701751799

Kelly M.M.; Chakir J.; Vethanayagam D.; Boulet L.P.; Laviiolette M.; Gauldie J.; O’Byrne P.M. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest. 2006, 130(3):741-753. doi:10.1378/chest.130.3.741 DOI: https://doi.org/10.1378/chest.130.3.741

Gauvreau G.M.; Plitt J.R.; Baatjes A.; MacGlashan D.W.; Expression of functional cysteinyl leukotriene receptors by human ba-sophils. J Allergy Clin Immunol. 2005, 116(1):80-87, doi:10.1016/j.jaci.2005.03.014 DOI: https://doi.org/10.1016/j.jaci.2005.03.014

Yonetomi Y.; Sekioka T.; Kadode M.; Kitamine Y.; Kamiya A.; Inoue A.; Nakao T.; Nomura H.; Murata M.; Nakao S.; Nambu F.; Fujita M.; Nakade S.; Kawabata K. Effects of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptors antagonist, in a guinea pig model of asthma. Eur J Pharmacol. 2015, 765:242-248, doi:10.1016/j.ejphar.2015.08.041 DOI: https://doi.org/10.1016/j.ejphar.2015.08.041

Sekioka T.; Kadode M.; Fujii M.; Kawabata K.; Abe T.; Horiba M.; Kohno S.; Nabe T. Expression of CysLT2 receptors in asthma lung, and their possible role in bronchoconstriction. Allergol Int. 2015, 64(4):351-358, doi:10.1016/j.alit.2015.04.008 DOI: https://doi.org/10.1016/j.alit.2015.04.008

Matsuda M.; Tabuchi Y.; Nishimura K.; Nakamura Y.; Sekioka T.; Kawabata K.; Nabe T. Increased expression of CysLT2 receptors in the lung of asthmatic mice and role in allergic responses. Prostaglandins Leukot Essent Fatty Acids. 2018, 131:24-31, doi:10.1016/j.plefa.2018.03.007 DOI: https://doi.org/10.1016/j.plefa.2018.03.007

Celik P.; Sakar A.; Havlucu Y.; Yuksel H.; Turkdogan P.; Yorgancioglu A.; Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med. 2005, 99(4):444-450, doi:10.1016/j.rmed.2004.09.008 DOI: https://doi.org/10.1016/j.rmed.2004.09.008

Duah E.; Adapala R.K.; Al-Azzam N.; Kondeti V.; Gombedza F.; Thodeti C.K.; Paruchuri S. Cysteinyl leukotrienes regulate endo-thelial cell inflammatory and proliferative signals through CysLT₂ and CysLT₁ receptors. Sci Rep. 2013, 3:3274, doi:10.1038/srep03274 DOI: https://doi.org/10.1038/srep03274

Bäck M. Inflammatory signaling through leukotriene receptors in atherosclerosis. Curr Atheroscler Rep. 2008, 10(3):244-251, doi:10.1007/s11883-008-0038-7 DOI: https://doi.org/10.1007/s11883-008-0038-7

Bäck M. Leukotriene receptors: crucial components in vascular inflammation. ScientificWorldJournal. 2007;7:1422-1439. doi:10.1100/tsw.2007.187 DOI: https://doi.org/10.1100/tsw.2007.187

Sala A.; Aliev G.M.; Rossoni G.; Berti F.; Buccellati C.; Burnstock G.; Folco G.; Maclouf J. Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit. Blood. 1996, 87(5):1824-1832. DOI: https://doi.org/10.1182/blood.V87.5.1824.bloodjournal8751824

Sala A.; Folco G.; Murphy R.C. Transcellular biosynthesis of eicosanoids. Pharmacol Rep. 2010, 62(3):503-510, doi: 10.1016/s1734-1140(10)70306-6 DOI: https://doi.org/10.1016/S1734-1140(10)70306-6

Di Gennaro A.; Carnini C.; Buccellati C.; Ballerio R.; Zarini S.; Fumagalli F.; Viappiani S.; Librizzi L.; Hernandez A.; Murphy R.C.; Constantin G.; De Curtis M.; Folco G.; Sala A. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cer-ebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB J. 2004, 18(7):842-844, doi:10.1096/fj.03-0599fje DOI: https://doi.org/10.1096/fj.03-0599fje

Singh R.K. Antagonism of cysteinyl leukotrienes and their receptors as a neuroinflammatory target in Alzheimer’s disease. Neurol Sci. 2020, 41(8):2081-2093, doi:10.1007/s10072-020-04369-7 DOI: https://doi.org/10.1007/s10072-020-04369-7

Singh R.K.; Tandon R.; Dastidar S.G.; Ray A. A review on leukotrienes and their receptors with reference to asthma. J Asthma. 2013, 50(9):922-931, doi:10.3109/02770903.2013.823447 DOI: https://doi.org/10.3109/02770903.2013.823447

Gelosa P.; Colazzo F.; Tremoli E.; Sironi L.; Castiglioni L. Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cere-bral Diseases. Mediators Inflamm. 2017, 2017:3454212, doi:10.1155/2017/3454212 DOI: https://doi.org/10.1155/2017/3454212

Khan H.; Gupta A.; Singh T.G.; Kaur A. Mechanistic insight on the role of leukotriene receptors in ischemic-reperfusion injury. Pharmacol Rep. 2021, 73(5):1240-1254, doi:10.1007/s43440-021-00258-8 DOI: https://doi.org/10.1007/s43440-021-00258-8

Wang Y.; Yang Y.; Zhang S.; Li C.; Zhang L. Modulation of neuroinflammation by cysteinyl leukotriene 1 and 2 receptors: impli-cations for cerebral ischemia and neurodegenerative diseases. Neurobiol Aging. 2020, 87:1-10, doi:10.1016/j.neurobiolaging.2019.12.013 DOI: https://doi.org/10.1016/j.neurobiolaging.2019.12.013

Huang X.Q.; Zhang X.Y.; Wang X.R.; Yu S.Y.; Fang S.H.; Lu Y.B.; Zhang W.P.; Wei E.Q. Transforming growth factor β1-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor 1. J Neuroinflammation. 2012, 9:145, doi:10.1186/1742-2094-9-145 DOI: https://doi.org/10.1186/1742-2094-9-145

Chen L.; Yang Y.; Li C.T.; Zhang S.R.; Zheng W.; Wei E.Q.; Zhang L.H. CysLT2 receptor mediates lipopolysaccharide-induced microglial inflammation and consequent neurotoxicity in vitro. Brain Res. 2015, 1624:433-445, doi:10.1016/j.brainres.2015.08.007 DOI: https://doi.org/10.1016/j.brainres.2015.08.007

Qi L.L.; Fang S.H.; Shi W.Z.; Huang X.Q.; Zhang X.Y.; Lu Y.B.; Zhang W.P.; Wei E.Q. CysLT2 receptor-mediated AQP4 up-regulation is involved in ischemic-like injury through activation of ERK and p38 MAPK in rat astrocytes. Life Sci. 2011, 88(1-2):50-56, doi:10.1016/j.lfs.2010.10.025 DOI: https://doi.org/10.1016/j.lfs.2010.10.025

Shi W.Z.; Zhao C.Z.; Zhao B.; Shi Q.J.; Zhang L.H.; Wang Y.F.; Fang S.H.; Lu Y.B.; Zhang W.P.; Wei E.Q. Aggravated inflammation and increased expression of cysteinyl leukotriene receptors in the brain after focal cerebral ischemia in AQP4-deficient mice. Neu-rosci Bull. 2012, 28(6):680-692. doi:10.1007/s12264-012-1281-z DOI: https://doi.org/10.1007/s12264-012-1281-z

Zhao C.Z.; Zhao B.; Zhang X.Y.; Huang X.Q.; Shi W.Z.; Liu H.L.; Fang S.H.; Lu Y.B.; Zhang W.P.; Tang F.D.; Wei E.Q. Cysteinyl leukotriene receptor 2 is spatiotemporally involved in neuron injury, astrocytosis and microgliosis after focal cerebral ischemia in rats. Neuroscience. 2011, 189:1-11, doi:10.1016/j.neuroscience.2011.05.066 DOI: https://doi.org/10.1016/j.neuroscience.2011.05.066

Zhang X.Y.; Wang X.R.; Xu D.M.; Yu S.Y.; Shi Q.J.; Zhang L.H.; Chen L.; Fang S.H.; Lu Y.B.; Zhang W.P.; Wei E.Q. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther. 2013, 346(2):328-341, doi:10.1124/jpet.113.203604 DOI: https://doi.org/10.1124/jpet.113.203604

Wunder F.; Tinel H.; Kast R.; Geerts A.; Becker E.M.; Kolkhof P.; Hutter J.; Erguden J.; Harter M. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor. Br J Pharmacol. 2010, 160(2):399-409, doi:10.1111/j.1476-5381.2010.00730.x DOI: https://doi.org/10.1111/j.1476-5381.2010.00730.x

Zhao R.; Ying M.; Gu S.; Yin W.; Li Y.; Yuan H.; Fang S.; Li M. Cysteinyl Leukotriene Receptor 2 is Involved in Inflammation and Neuronal Damage by Mediating Microglia M1/M2 Polarization through NF-κB Pathway. Neuroscience. 2019, 422:99-118, doi:10.1016/j.neuroscience.2019.10.048 DOI: https://doi.org/10.1016/j.neuroscience.2019.10.048

Shi Q.J.; Wang H.; Liu Z.X.; Fang S.H.; Song X.M.; Lu Y.B.; Zhang W.P.; Sa X.Y.; Ying H.Z.; Wei E.Q. HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience. 2015, 291:53-69, doi:10.1016/j.neuroscience.2015.02.002 DOI: https://doi.org/10.1016/j.neuroscience.2015.02.002

Shi Q.J.; Xiao L.; Zhao B.; Zhang X.Y.; Wang X.R.; Xu D.M.; Yu S.Y.; Fang S.H.; Lu Y.B.; Zhang W.P.; Sa X.Y.; Wei E.Q. Intracer-ebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Res. 2012, 1484:57-67, doi:10.1016/j.brainres.2012.09.020 DOI: https://doi.org/10.1016/j.brainres.2012.09.020

Shi S.S.; Yang W.Z.; Tu X.K.; Wang C.H.; Chen C.M.; Chen Y. 5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia. Inflammation. 2013, 36(6):1209-1217, doi:10.1007/s10753-013-9657-4 DOI: https://doi.org/10.1007/s10753-013-9657-4

Ciceri P.; Rabuffetti M.; Monopoli A.; Nicosia S. Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br J Pharmacol. 2001, 133(8):1323-1329, doi:10.1038/sj.bjp.0704189 DOI: https://doi.org/10.1038/sj.bjp.0704189

Saad M.A.; Abdelsalam R.M.; Kenawy S.A.; Attia A.S. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats. Neurochem Res. 2015, 40(1):139-150. doi:10.1007/s11064-014-1478-9 DOI: https://doi.org/10.1007/s11064-014-1478-9

Gelosa P.; Bonfanti E.; Castiglioni L.; Delgado-Garcia J.; Gruart A.; Fontana L.; Gotti M.; Tremoli E.; Lecca D.; Fumagalli M.; Cimino M.; Aigner L.; Abbracchio M.P.; Sironi L. Improvement of fiber connectivity and functional recovery after stroke by mon-telukast, an available and safe anti-asthmatic drug. Pharmacol Res. 2019, 142:223-236. doi:10.1016/j.phrs.2019.02.025 DOI: https://doi.org/10.1016/j.phrs.2019.02.025

Zhao R.; Shi W.Z.; Zhang Y.M.; Fang S.H.; Wei E.Q. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. J Pharm Pharmacol. 2011, 63(4):550-557. doi:10.1111/j.2042-7158.2010.01238.x DOI: https://doi.org/10.1111/j.2042-7158.2010.01238.x

Fang S.H.; Wei E.Q.; Zhou Y.; Wang M.L.; Zhang W.P.; Yu G.L.; Chu L.S.; Chen Z. Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience. 2006;140(3):969-979. doi:10.1016/j.neuroscience.2006.02.051 DOI: https://doi.org/10.1016/j.neuroscience.2006.02.051

Becher UM, Ghanem A, Tiyerili V, Fürst DO, Nickenig G, Mueller CFH. Inhibition of leukotriene C4 action reduces oxidative stress and apoptosis in cardiomyocytes and impedes remodeling after myocardial injury. J Mol Cell Cardiol. 2011, 50(3):570-577. doi:10.1016/j.yjmcc.2010.11.013 DOI: https://doi.org/10.1016/j.yjmcc.2010.11.013

Hoxha M.; Rovati G.E.; Cavanillas A.B. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. Eur J Clin Pharmacol. 2017, 73(7):799-809. doi:10.1007/s00228-017-2242-2 DOI: https://doi.org/10.1007/s00228-017-2242-2

Ni N.C.; Ballantyne L.L.; Mewburn J.D.; Funk C.D. Multiple-site activation of the cysteinyl leukotriene receptor 2 is required for exacerbation of ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2014, 34(2):321-330. doi:10.1161/ATVBAHA.113.302536 DOI: https://doi.org/10.1161/ATVBAHA.113.302536

Ni N.C.; Yan D.; Ballantyne L.L.; Barajas-Espinoza A.; St Amand T.; Pratt D.A.; Funk C.D A selective cysteinyl leukotriene re-ceptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. J Pharmacol Exp Ther. 2011, 339(3):768-778. doi:10.1124/jpet.111.186031 DOI: https://doi.org/10.1124/jpet.111.186031

Ito T.; Toki Y.; Hieda N.; Okumura K.; Hashimoto H.; Ogawa K.; Satake T. Protective effects of a thromboxane synthetase inhibi-tor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. Jpn Circ J. 1989, 53(9):1115-1121. doi:10.1253/jcj.53.1115 DOI: https://doi.org/10.1253/jcj.53.1115

Chu L.S.; Wei E.Q.; Yu G.L.; Fang S.H.; Zhou Y,; Wang M.L.; Zhang W.P. Pranlukast reduces neutrophil but not macro-phage/microglial accumulation in brain after focal cerebral ischemia in mice. Acta Pharmacol Sin. 2006, 27(3):282-288. doi:10.1111/j.1745-7254.2006.00290.x DOI: https://doi.org/10.1111/j.1745-7254.2006.00290.x

Allen S.; Dashwood M.; Morrison K.; Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coro-nary arteries. Circulation. 1998, 97(24):2406-2413. doi:10.1161/01.cir.97.24.2406 DOI: https://doi.org/10.1161/01.CIR.97.24.2406

Carnini C.; Accomazzo M.R.; Borroni E.; Vitellaro-Zuccarello L.; Durand T.; Folco G.; Rovati G.E.; Capra V.; Sala A. Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J. 2011, 25(10):3519-3528. doi:10.1096/fj.10-177030 DOI: https://doi.org/10.1096/fj.10-177030

Jiang W.; Hall S.R.; Moos M.P.W.; Cao R.Y. Ishii S.; Ogunyankin K.O.; Melo L.G.; Funk C.D. Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am J Pathol. 2008, 172(3):592-602. doi:10.2353/ajpath.2008.070834 DOI: https://doi.org/10.2353/ajpath.2008.070834

Mueller C.F.H.; Wassmann K.; Widder J.D.; Wassmann S.; Chen C.H.; Keuler B.; Kudin A.; Kunz W.S.; Nickenig G. Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation. 2008, 117(22):2912-2918. doi:10.1161/CIRCULATIONAHA.107.747667 DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.747667

Bäck M.; Hansson G.K.; Leukotriene receptors in atherosclerosis. Ann Med. 2006, 38(7):493-502. doi:10.1080/07853890600982737 DOI: https://doi.org/10.1080/07853890600982737

Gautier-Veyret E.; Bäck M.; Arnaud C.; Belaidi E.; Tamisier R.; Levy P.; Arnol N.; Perrin M.; Pepin J.L.; Stanke-Labesque F. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome. Pharmacol Res. 2018, 134:311-319. doi:10.1016/j.phrs.2018.06.014 DOI: https://doi.org/10.1016/j.phrs.2018.06.014

Jawien J.; Gajda M.; Rudling M.; Mateuszuk L.; Olszanecki R.; Guzik T.J.; Cichocki T.; Chlopicki S.; Korbut R. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest. 2006, 36(3):141-146. doi:10.1111/j.1365-2362.2006.01606.x DOI: https://doi.org/10.1111/j.1365-2362.2006.01606.x

Jawień J.; Gajda M.; Olszanecki R.; Korbut R.; BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007, 58(3):583-588.

Jawien J.; Gajda M.; Wołkow P.; Zurańska J.; Olszanecki R.; Korbut R.; The effect of montelukast on atherogenesis in ap-oE/LDLR-double knockout mice. J Physiol Pharmacol. 2008, 59(3):633-639.

Liu D.; Ge S.; Zhou G.; Xu G.; Zhang R.; Zhu W.; Liu Z.; Cheng S.; Liu X. Montelukast inhibits matrix metalloproteinases ex-pression in atherosclerotic rabbits. Cardiovasc Drugs Ther. 2009, 23(6):431-437. doi:10.1007/s10557-009-6211-6 DOI: https://doi.org/10.1007/s10557-009-6211-6

Di Gennaro A.; Araújo A.C.; Busch A.; Jin H.; Wagsater D.; Vorkapic E.; Caidahl K.; Eriksson P.; Sammuelsson B.; Maegdefessel L.; Maeggstrom J. Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm. Proc Natl Acad Sci U S A. 2018, 115(8):1907-1912. doi:10.1073/pnas.1717906115 DOI: https://doi.org/10.1073/pnas.1717906115

Kawai Y.; Narita Y.; Yamawaki-Ogata A.; Usui A.; Komori K.; Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation. Biomed Res Int. 2019, 2019:9104680. doi:10.1155/2019/9104680 DOI: https://doi.org/10.1155/2019/9104680

Di Gennaro A.; Wågsäter D.; Mäyränpää M.I.; Gabrielsen A.; Swedenborg J.; Hamsten A.; Samuelsson B.; Eriksson P.; Haegg-strom J. Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human ab-dominal aortic aneurysm. Proc Natl Acad Sci U S A. 2010, 107(49):21093-21097. doi:10.1073/pnas.1015166107 DOI: https://doi.org/10.1073/pnas.1015166107

Rahman S.O.; Singh R.K.; Hussain S.; Akhtar M.; Najmi A.K. A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer’s disease. Eur J Pharmacol. 2019, 842:208-220. doi:10.1016/j.ejphar.2018.10.040 DOI: https://doi.org/10.1016/j.ejphar.2018.10.040

Firuzi O.; Zhuo J.; Chinnici C.M.; Wisniewski T.; Praticò D. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer’s disease. FASEB J. 2008, 22(4):1169-1178. doi:10.1096/fj.07-9131.com DOI: https://doi.org/10.1096/fj.07-9131.com

Hsieh H.L.; Yang C.M. Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed Res Int. 2013, 2013:484613. doi:10.1155/2013/484613 DOI: https://doi.org/10.1155/2013/484613

Lai J.; Hu M.; Wang H.; Hu M.; Long Y.; Miao M.X.; Li J.C.; Wang X.B.; Kong L.Y.; Hong H. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology. 2014, 79:707-714. doi:10.1016/j.neuropharm.2014.01.011 DOI: https://doi.org/10.1016/j.neuropharm.2014.01.011

Michael J.; Marschallinger J.; Aigner L. The leukotriene signaling pathway: a druggable target in Alzheimer’s disease. Drug Dis-cov Today. 2019, 24(2):505-516. doi:10.1016/j.drudis.2018.09.008 DOI: https://doi.org/10.1016/j.drudis.2018.09.008

Chu J.; Praticò D. Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer’s disease mouse model. J Neuroinflammation. 2012, 9:127. doi:10.1186/1742-2094-9-127 DOI: https://doi.org/10.1186/1742-2094-9-127

Ishikura Y.; Maeda-Minami A.; Hosokawa M.; Onoda A.; Kawano Y.; Ihara T.; Sugamata M.; Takeda K.; Mano Y. Leukotriene Receptor Antagonist Use and Dementia Risk in Patients With Asthma: A Retrospective Cohort Study. In Vivo. 2021, 35(6):3297-3303. doi:10.21873/invivo.12625 DOI: https://doi.org/10.21873/invivo.12625

Hajjar I. Effects of Montelukast Therapy on Alzheimer’s Disease (EMERALD). https://clinicaltrials.gov/ct2/show/NCT03991988 (na dzień: 16 czerwca 2022)

Wallin J.; Svenningsson P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflamma-tion in Parkinson’s Disease. Int J Mol Sci. 2021, 22(11):5606. doi:10.3390/ijms22115606 DOI: https://doi.org/10.3390/ijms22115606

Lai J.; Mei Z.L.; Wang H.; Hu M.; Long Y.; Miao M.X.; Li N. Hong H. Montelukast rescues primary neurons against Aβ1-42-induced toxicity through inhibiting CysLT1R-mediated NF-κB signaling. Neurochem Int. 2014, 75:26-31. doi:10.1016/j.neuint.2014.05.006 DOI: https://doi.org/10.1016/j.neuint.2014.05.006

Marschallinger J.; Schäffner I., Klein B.; Gelfert R.; Rivera F.J.; Illes S.; Grassner L.; Janssen M.; Rotheneichner P.; Schmuckermair C.; Coras R.; Boccazzi M.; Chishty M.; Lagler F.B.; Renic M.; Bauer H.C.; Singewald N.; Blumcke I.; Bogdahn U.; Couil-lard-Despres S.; Lie D.C.; Abbracchio M.P.; Aigner L. Structural and functional rejuvenation of the aged brain by an approved an-ti-asthmatic drug. Nat Commun. 2015, 6:8466. doi:10.1038/ncomms9466 DOI: https://doi.org/10.1038/ncomms9466

Kang K.H.; Liou H.H.; Hour M.J.; Liou H.C.; Fu W.M. Protection of dopaminergic neurons by 5-lipoxygenase inhibitor. Neuro-pharmacology. 2013, 73:380-387. doi:10.1016/j.neuropharm.2013.06.014 DOI: https://doi.org/10.1016/j.neuropharm.2013.06.014

Jang H.; Kim S.; Lee J.M.; Oh Y.S.; Park S.M.; Kim S.R. Montelukast treatment protects nigral dopaminergic neurons against mi-croglial activation in the 6-hydroxydopamine mouse model of Parkinson’s disease. Neuroreport. 2017, 28(5):242-249. doi:10.1097/WNR.0000000000000740 DOI: https://doi.org/10.1097/WNR.0000000000000740

Tsai M.J.; Chang W.A.; Chuang C.H.; Wu K.L.; Cheng C.H.; Sheu C.C.; Hsu Y.L.; Hung J.Y. Cysteinyl Leukotriene Pathway and Cancer. Int J Mol Sci. 2021, 23(1):120. doi:10.3390/ijms23010120 DOI: https://doi.org/10.3390/ijms23010120

Burke L.; Butler C.T.; Murphy A.; Moran B.; Gallagher W.M.; O’Sullivan J.; Kennedy B.N. Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. Front Cell Dev Biol. 2016, 4:103. doi:10.3389/fcell.2016.00103 DOI: https://doi.org/10.3389/fcell.2016.00103

Duah E.; Teegala L.R.; Kondeti V.; Adapala R.K.; Keshamouni V.; Kanaoka Y.; Austen K.F.; Thodeti C.K.; Parachuri S. Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis. PNAS. 2019, 116(1):199-204. doi:10.1073/pnas.1817325115 DOI: https://doi.org/10.1073/pnas.1817325115

Bellamkonda K.; Satapathy S.R.; Douglas D.; Chandrashekar N.; Selvanesan B.; Liu M.; Savari S.; Jonsson G.; Sjolander A. Mon-telukast, a CysLT1 receptor antagonist, reduces colon cancer stemness and tumor burden in a mouse xenograft model of human co-lon cancer. Cancer Lett. 2018, 437:13-24. doi:10.1016/j.canlet.2018.08.019 DOI: https://doi.org/10.1016/j.canlet.2018.08.019

Bengtsson A.M.; Jönsson G.; Magnusson C.; Salim T.; Axelsson C.; Sjölander A. The cysteinyl leukotriene 2 receptor contributes to all-trans retinoic acid-induced differentiation of colon cancer cells. BMC Cancer. 2013, 13:336. doi:10.1186/1471-2407-13-336 DOI: https://doi.org/10.1186/1471-2407-13-336

Barajas-Espinosa A.; Ochoa-Cortes F.; Moos M.P.; Ramirez F.D.; Vanner S.J.; Funk C.D. Characterization of the cysteinyl leuko-triene 2 receptor in novel expression sites of the gastrointestinal tract. Am J Pathol. 2011, 178(6):2682-2689. doi:10.1016/j.ajpath.2011.02.041 DOI: https://doi.org/10.1016/j.ajpath.2011.02.041

Magnusson C.; Mezhybovska M.; Lörinc E.; Fernebro E.; Nilbert M.; Sjölander A. Low expression of CysLT1R and high expres-sion of CysLT2R mediate good prognosis in colorectal cancer. Eur J Cancer. 2010, 46(4):826-835. doi:10.1016/j.ejca.2009.12.022 DOI: https://doi.org/10.1016/j.ejca.2009.12.022

Drost A.C.; Seitz G.; Boehmler A.; Funk M.; Norz K.P.; Zipfel A.; Xue X.; Kanz L.; Mohle R. The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia. Leuk Lymphoma. 2012, 53(4):665-673. doi:10.3109/10428194.2011.625578 DOI: https://doi.org/10.3109/10428194.2011.625578

Savari S.; Liu M.; Zhang Y.; Sime W.; Sjölander A. CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer. PLoS One. 2013, 8(9):e73466. doi:10.1371/journal.pone.0073466 DOI: https://doi.org/10.1371/journal.pone.0073466

COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6 (na dzień: 16 czerwca 2022)

Aigner L.; Pietrantonio F.; Bessa de Sousa D.M.; Michael J.; Schuster D.; Reitsamer H.; Zerbe H.; Studnicka M. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic. Front Mol Biosci. 2020, 7:610132. doi:10.3389/fmolb.2020.610132 DOI: https://doi.org/10.3389/fmolb.2020.610132

Anderson R.; Theron A.J.; Gravett C.M.; Steel H.C.; Tintinger G.R.; Feldman C. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol. 2009, 156(1):105-115. doi:10.1111/j.1476-5381.2008.00012.x DOI: https://doi.org/10.1111/j.1476-5381.2008.00012.x

Dey M.; Singh R.K. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19. Pharmacology. 2021, 106(9-10):469-476. doi:10.1159/000518359 DOI: https://doi.org/10.1159/000518359

Trinh H.K.T.; Nguyen T.V.T.; Choi Y.; Park H.S.; Shin Y.S. The synergistic effects of clopidogrel with montelukast may be benefi-cial for asthma treatment. J Cell Mol Med. 2019, 23(5):3441-3450. doi:10.1111/jcmm.14239 DOI: https://doi.org/10.1111/jcmm.14239

May B.C.; Gallivan K.H. Levocetirizine and montelukast in the COVID-19 treatment paradigm. Int Immunopharmacol. 2022, 103:108412. doi:10.1016/j.intimp.2021.108412 DOI: https://doi.org/10.1016/j.intimp.2021.108412

Cardani A.; Boulton A.; Kim T.S.; Braciale T.J. Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infec-tion Of Type-1 Alveolar Epithelial Cells. PLoS Pathog. 2017, 13(1):e1006140. doi:10.1371/journal.ppat.1006140 DOI: https://doi.org/10.1371/journal.ppat.1006140

Wu C.; Liu Y.; Yang Y.; Zhang P.; Zhong W.; Wang Y.; Wang Q.; Xu Y.; Li M.; Li X.; Zheng M.; Chen L.; Li H. Analysis of ther-apeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020, 10(5):766-788. doi:10.1016/j.apsb.2020.02.008 DOI: https://doi.org/10.1016/j.apsb.2020.02.008

Durdagi S.; Avsar T.; Orhan M.D.; Serhatli M.; Balcioglu B.K.; Ozturk H.U.; Kayabolen A.; Cetin Y.; Aydinlik S.; Bagci-Onder T.; Tekin S.; Demirci H.; Guzel M.; Akdemir A.; Calis S.; Oktay L.; Tolu I.; Butun Y.E.; Erdemoglu E.; Olkan A.; Tokay N.; Isik S.; Ozcan A.; Acar E.; Buyukkilic S.; Yumak Y. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies. Mol Ther. 2022, 30(2):963-974. doi:10.1016/j.ymthe.2021.10.014 DOI: https://doi.org/10.1016/j.ymthe.2021.10.014

Khan A.R.; Misdary C.; Yegya-Raman N.; Kim S.; Narayanan N.; Siddiqui S.; Salgame P.; Radbel J.; Grotte F.D.; Michel C.; Mehnert J.; Hernandez C.; Braciale T.; Malhorta J.; Gentile M.A.; Jabbour S.K. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2021, 1-7. doi:10.1080/02770903.2021.1881967 DOI: https://doi.org/10.21203/rs.3.rs-52430/v1

Thompson M.D.; Capra V.; Clunes M.T.; Rovati G.E.; Stankova J.; Maj M.C.; Duffy D.L. Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies. Front Pharmacol. 2016, 7:299. doi:10.3389/fphar.2016.00299 DOI: https://doi.org/10.3389/fphar.2016.00299

Thompson M.D.; Cole D.E.C.; Capra V.; Siminovitch K.A.; Rovati G.E.; Burnham W.M.; Rana B.K. Pharmacogenetics of the G protein-coupled receptors. Methods Mol Biol. 2014, 1175:189-242. doi:10.1007/978-1-4939-0956-8_9 DOI: https://doi.org/10.1007/978-1-4939-0956-8_9

Slater K.; Hoo P.S.; Buckley A.M.; Piulats J.M.; Villanueva A.; Portela A.; Kennedy B.N. Evaluation of oncogenic cysteinyl leu-kotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer Metastasis Rev. 2018, 37(2-3):335-345. doi:10.1007/s10555-018-9751-z DOI: https://doi.org/10.1007/s10555-018-9751-z

Moore A.R.; Ceraudo E.; Sher J.J.; Guan Y.; Shoushtari A.; Chang M.T.; Zhang J.Q.; Walczak E.G.; Kazmi M.A.; Taylor B.S.; Hu-ber T.; Chi P.; Sakmar T.P.; Chen Y. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 2016, 48(6):675-680. doi:10.1038/ng.3549 DOI: https://doi.org/10.1038/ng.3549

Ceraudo E.; Horioka M.; Mattheisen J.M.; Hitchman T.D.; Moore A.R.; Kazmi M.A.; Chi P.; Chen Y.; Sakmar T.P.; Huber T. Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. J Biol Chem. 2021, 296:100163. doi:10.1074/jbc.RA120.015352 DOI: https://doi.org/10.1074/jbc.RA120.015352

Montuschi P.; Peters-Golden M.L. Leukotriene modifiers for asthma treatment. Clin Exp Allergy. 2010, 40(12):1732-1741. doi:10.1111/j.1365-2222.2010.03630.x DOI: https://doi.org/10.1111/j.1365-2222.2010.03630.x

Akin-Bali D.F. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma. Ophthalmic Genet. 2021, 42(6):732-743. doi:10.1080/13816810.2021.1961280 DOI: https://doi.org/10.1080/13816810.2021.1961280

Nell R.J.; Menger N.V.; Versluis M.; Luyten G.P.; Verdijk R.M.; Madigan M.C.; Jager M.J.; van der Velden P. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma. BMC Cancer. 2021, 21(1):164. doi:10.1186/s12885-021-07865-x DOI: https://doi.org/10.1186/s12885-021-07865-x

Möller I.; Murali R.; Müller H.; Wiesner T.; Jackett L.A.; Scholz S.L.; Cosgarea I.; van de Nes J.; Sucker A.; Hillen .; Schilling B.; Paschen A.; Kutzner H.; Rutten A.; Bockers M.; Scolyer R.A.; Schadendorf D.; Griewank K.G. Activating cysteinyl leukotriene re-ceptor 2 (CYSLTR2) mutations in blue nevi. Mod Pathol. 2017, 30(3):350-356. doi:10.1038/modpathol.2016.201 DOI: https://doi.org/10.1038/modpathol.2016.201

Goto K.; Pissaloux D.; Paindavoine S.; Tirode F.; de la Fouchardière A. CYSLTR2-mutant Cutaneous Melanocytic Neoplasms Frequently Simulate “Pigmented Epithelioid Melanocytoma,” Expanding the Morphologic Spectrum of Blue Tumors: A Clinico-pathologic Study of 7 Cases. Am J Surg Pathol. 2019, 43(10):1368-1376. doi:10.1097/PAS.0000000000001299 DOI: https://doi.org/10.1097/PAS.0000000000001299

Brochu-Bourque A.; Véronneau S.; Rola-Pleszczynski M.; Stankova J. Differential signaling defects associated with the M201V polymorphism in the cysteinyl leukotriene type 2 receptor. J Pharmacol Exp Ther. 2011, 336(2):431-439. doi:10.1124/jpet.110.172411 DOI: https://doi.org/10.1124/jpet.110.172411

Cornejo-García J.A.; Perkins J.R.; Jurado-Escobar R.; Garcia-Martin E.; Agundez J.A.; Viguera E.; Perez-Sanchez N.; Blan-ca-Lopez N. Pharmacogenomics of Prostaglandin and Leukotriene Receptors. Front Pharmacol. 2016, 7:316. doi:10.3389/fphar.2016.00316 DOI: https://doi.org/10.3389/fphar.2016.00316

Ji T.; Lu T.; Qiu Y.; Li X.; Liu Y.; Tai J.; Guo Y.; Zhang J.; Wang S.; Zhao J.; Ni X.; Xu Z. The efficacy and safety of montelukast in children with obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med. 2021, 78:193-201. doi:10.1016/j.sleep.2020.11.009 DOI: https://doi.org/10.1016/j.sleep.2020.11.009

Dixon E.G.; Rugg-Gunn C.E.; Sellick V.; Sinha I.P.; Hawcutt D.B. Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review. BMJ Paediatr Open. 2021, 5(1):e001206. doi:10.1136/bmjpo-2021-001206 DOI: https://doi.org/10.1136/bmjpo-2021-001206

Okunishi K.; Peters-Golden M. Leukotrienes and airway inflammation. Biochim Biophys Acta. 2011, 1810(11):1096-1102. doi:10.1016/j.bbagen.2011.02.005 DOI: https://doi.org/10.1016/j.bbagen.2011.02.005

Dong X.; Wang L.; Huang X.; Liu T.; Wei E.; Du E.; Yang B.; Hu Y. Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists. Bioorg. Med. Chem. 2010, 18(15):5519-5527. doi:10.1016/j.bmc.2010.06.047 DOI: https://doi.org/10.1016/j.bmc.2010.06.047

Dong X.; Zhao Y.; Huang X.; Lin K.; Chen J.; Wei E.; Liu T.; Hu Y. Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists. Eur J Med Chem. 2013, 62:754-763. doi:10.1016/j.ejmech.2013.01.041 DOI: https://doi.org/10.1016/j.ejmech.2013.01.041

Luginina A.; Gusach A.; Marin E.; Mishin E.; Brouillette R.; Popov P.; Shiriaeva A.; Besserer-Offroy E.; Longpre J.M.; Lyapina E.; Ishchenko A.; Patel N.; Polovinkin V.; Safronova N.; Bogorodskiy A.; Edelweiss E.; Hu H.; Weierstall U.; Liu W.; Batyuk A.; Gordeliy V.; Han G.W.; Sarret P.; Katritch V.; Borshchevskiy V.; Cherezov V. Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs. Sci Adv. 2019, 5(10):eaax2518. doi:10.1126/sciadv.aax2518 DOI: https://doi.org/10.1126/sciadv.aax2518

Gusach A.; Luginina A.; Marin E.; Brouillette R.L.; Besserer-Offroy E.; Longpre J.M.; Ishchenko A.; Popov P.; Patel N.; Fujimoto T.; Maruyama T.; Stauch B.; Ergasheva M.; Romanovskaia D.; Stepko A.; Kovalev K.; Shevtsov M.; Gordeily V.; Han G.W.; Kat-ritch V.; Borshchevskiy V.; Sarret P.; Mishin A.; Cherezov V. Structural basis of ligand selectivity and disease mutations in cyste-inyl leukotriene receptors. Nat Commun. 2019, 10(1):5573. doi:10.1038/s41467-019-13348-2 DOI: https://doi.org/10.1038/s41467-019-13348-2

Marin E.; Luginina A.; Gusach A.; Kovalev K.; Bukshdruker S.; Khorn P.; Polovinkin V.; Lyapina E.; Rogachev A.; Gordeliy V.; Mishin A.; Cherezov V.; Borshchevskiy V. Small-wedge synchrotron and serial XFEL datasets for Cysteinyl leukotriene GPCRs. Sci Data. 2020, 7(1):388. doi:10.1038/s41597-020-00729-2 DOI: https://doi.org/10.1038/s41597-020-00729-2

Bartłomiej Pyrak

b.pyrak12@gmail.com

Affiliation:

Student Scientific Association « Free Radicals », Department of Physical Chemistry, Medical University of Warsaw, Warsaw, Poland Poland

Karolina Rogacka

Affiliation:

Department of Geriatrics, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland Poland

Dariusz Maciej Pisklak

Affiliation:

Department of Physical Chemistry, Medical University of Warsaw, Warsaw, Poland Poland

Anti-leukotriene drugs in the therapy of inflammatory diseases

Bartłomiej Pyrak

Karolina Rogacka

Dariusz Maciej Pisklak

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Bartłomiej Pyrak

Karolina Rogacka

Dariusz Maciej Pisklak